Characteristics | N 113 | % |
---|---|---|
Age (median, range) | 62 (33–80) | |
ECOG PS (median, range) | 1 (0–2) | |
De novo metastatic disease | 10 | (8.8) |
ER status | ||
Positive | 87 | (77.0) |
Negative | 26 | (23.0) |
PgR status | ||
Positive | 72 | (63.7) |
Negative | 38 | (33.6) |
Unk | 3 | (2.7) |
Triple negative | 22 | (19.5) |
HER2 status | ||
Positive | 11 | (9.7) |
Negative | 95 | (84.1) |
Unk | 7 | (6.2) |
Neo/adjuvant chemotherapy | 82 | (72.5) |
Adjuvant hormonotherapy | 67 | (59.3) |
Adjuvant trastuzumab | 4 | (3.5) |
Number of prior chemotherapy for advanced disease | ||
1 | 8 | (7.1) |
2 | 26 | (23.0) |
3 | 34 | (30.1) |
4 | 20 | (17.7) |
5 | 14 | (12.4) |
≥6 | 11 | (9.7) |
Median, range | 3 (1–10) | |
Prior hormonotherapy for advanced disease | 79 | (69.9) |
Median, range | 2 (1–5) | |
Number of organs involved | ||
1 | 17 | (15.0) |
2 | 43 | (38.1) |
3 | 33 | (29.2) |
≥4 | 20 | (17.7) |
Median, range | 2 (1–5) | |
Most common metastatic sites | ||
Bone | 81 | (71.7) |
Liver | 60 | (53.1) |
Lymph nodes | 48 | (42.5) |
Lung | 36 | (31.8) |
Skin | 19 | (16.8) |
CNS | 13 | (11.5) |
Rechallenge with anthracyclines and/or taxanes | 64 | (56.6) |